QCG
PRQR icon

Quadrant Capital Group’s ProQR Therapeutics PRQR Stock Holding History

Quadrant Capital Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,488
Closed -$14.5K – 2824
2024
Q4 		$14.5K Buy
+5,488
New +$17.4K ﹤0.01% 2004
2022
Q1 		– Sell
-3,840
Closed -$31K – 2654
2021
Q4 		$31K Buy
3,840
+1,196
+45% +$9.11K ﹤0.01% 1104
2021
Q3 		$22K Buy
2,644
+119
+5% +$777 ﹤0.01% 1202
2021
Q2 		$17K Buy
+2,525
New +$16.3K ﹤0.01% 1298

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Quadrant Capital Group's PRQR Position: Q1 2025 in Review

Quadrant Capital Group sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 5,488 shares — an estimated $14.5K sold.

Quadrant Capital Group first reported a position in PRQR in Q2 2021 and held it in 4 quarters. The position peaked at $31K in Q4 2021. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

  • Quadrant Capital Group reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 5,488 ProQR Therapeutics shares in Q1 2025, an estimated $14.5K.
  • Quadrant Capital Group first reported a position in ProQR Therapeutics in Q2 2021 and held it in 4 quarters.
  • Quadrant Capital Group's ProQR Therapeutics position peaked at $31K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on Quadrant Capital Group's 13F filing for Q1 2025, filed 13 May 2025.